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Abstract  
Amyloid-beta peptides (Aβ), implicated in Alzheimer’s disease (AD), interact with 
the cellular membrane and induce amyloid toxicity. The composition of cellular 
membranes changes in aging and AD. We designed multi-component lipid models 
to mimic healthy and diseased states of the neuronal membrane. Using atomic force 
microscopy (AFM), Kelvin probe force microscopy (KPFM) and black lipid 
membrane (BLM) techniques, we demonstrated that these model membranes differ 
in their nanoscale structure and physical properties, and interact differently with 
Aβ.  Based on our data, we propose a new hypothesis that changes in lipid 
membrane due to aging and AD may trigger amyloid toxicity through electrostatic 
mechanisms, similar to the accepted mechanism of antimicrobial peptide action. 
Understanding the role of the membrane changes as a key activating amyloid 
toxicity may aid in the development of a new avenue for the prevention and 
treatment of AD.  
Introduction 
Alzheimer’s disease (AD) is a progressive neurodegenerative disease which leads to 
severe impairment of memory and cognitive function and is characterized by the 
formation of amyloid-beta (Aβ) protein aggregates on neurons and cerebral blood 
vessels1, 2. While all amyloid aggregates, such as oligomers, fibrils, and plaques serve as 
cellular hallmarks of AD,  small soluble oligomers have recently been shown to be more 
toxic to cells than larger fibrils3. There is currently no cure or prevention for AD; 
prospective strategies to prevent amyloid toxicity include inhibiting the formation of 
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toxic oligomers, as well as preventing amyloid-damaging effect to the cellular membrane. 
In this work we propose and test a new hypothesis that changes in lipid membrane 
structure and properties may trigger amyloid toxicity. 
It is known that Aβ aggregation occurs on the surfaces of neuronal cells, leading to 
amyloid plaque formation in the brain tissues of individuals diagnosed with AD1, 2. The 
cellular membrane is therefore recognized as a target for amyloid attack. Aβ-membrane 
interactions may occur through specific membrane receptors4 as well as non-specifically 
with the lipid membranes themselves. Many studies have reported the effect of the 
membrane in general, and of lipid rafts on amyloid binding and toxicity3, 5-13. Despite 
these efforts, the molecular mechanism of amyloid toxicity remains unclear, which delays 
the development of a treatment for AD. Previous studies on the brain membrane lipid 
composition of AD patients have reveal changes in lipid composition that occur during 
disease progression. These include lowering the content of several types of phospholipids 
found in the inner leaflet of the membrane14 and a decrease in sphingomyelin (SM) 
content due to increased sphingomyelinase activity15. Perhaps surprisingly, the role of 
these changes has not been investigated in relation to amyloid toxicity. One type of 
neuronal lipids – gangliosides - is of special interest, with some contradicting results as to 
what occurs to their levels as a result of AD. Reductions in the amount of gangliosides 
present in the membrane have been observed in several regions of AD brains compared to 
that of control brains16-18 while other studies have suggested ganglioside plays a role in 
the formation of plaques and an increase in ganglioside 
monosialotetrahexosylganglioside (GM1) results in an increase of Aβ aggregation in vitro 
19-21. However, changes in membrane lipid composition may occur before the onset of 
AD symptoms and its corresponding cellular pathology. Recently, researchers 
demonstrated the predictive power of such changes in lipid composition in blood plasma 
as an early indicator of AD22. Changes in the composition of lipids found in blood plasma 
may be related to the changes in the lipid composition of neuronal membranes and /or 
membrane damage. Therefore it is of great interest to study the changes of structure and 
composition in neuronal membranes and their relevance to the amyloid-induced 
membrane damage, as these membrane changes may serve as an important switch to 
activate amyloid toxicity.  
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Biological cellular membranes are very complex and therefore model monolayers and 
bilayers are widely used to mimic the cellular membrane23, 24. While lipid models are 
very valuable for studying the mechanism of Aβ toxicity, earlier studies on model 
membranes cannot be easily related to in vivo animal and cellular studies, due to the fact 
that often, very simple models, composed of one or few lipid types,  are used5, 6, 8, 12, 13, 25-
30. Investigation of more complex model membranes will bridge our understanding of 
model systems and in vivo systems. In recent work, Sasahara et al. investigated the 
behaviour of Aβ in association with a lipid model containing five lipid constituents31, and 
Bennett et al examined 29 neurolipidomic datasets and found evidence to support the idea 
of phospholipid metabolism having an important determinant in the conversion of AD32. 
Here, our goal is to not only increase membrane complexity to better mimic neuronal 
membrane, but most importantly to mimic healthy and AD states of neuronal cell 
membranes and elucidate the role of membrane changes in amyloid toxicity.  
Currently, there are no lipid models mimicking healthy and AD neuronal membranes 
available in the literature, despite analysis of brain tissues showing changes in lipid 
composition with aging and AD19, 33, 34. Based on previous reports31, 35, 36, we developed a 
membrane model that incorporates DPPC, POPC, sphingomyelin, cholesterol, and 
ganglioside GM1. These lipids are found in the outer leaflet of neuronal cell membranes6, 
19, 33, 37. We hypothesize that changes in lipid composition of the AD brain affect the 
physical and structural properties of the neuronal cell membrane, compared to a healthy 
membrane, and that these changes in membrane fluidity, permeability, and lipid domain 
(raft) distribution, affect amyloid binding and make the neuronal membrane more 
susceptible to Aβ induced injury. 
In order to test this hypothesis, we designed multicomponent lipid models that mimic 
healthy and diseased states of neuronal cell membrane, with the goal of elucidating 
structural differences between these models as well as the differences in Aβ binding and 
the damage that Aβ produces to the healthy versus AD model membranes. We used 
AFM and KPFM imaging to reveal the surface morphology and electrical surface 
potential of monolayers associated with these models. We used AFM imaging in liquid 
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to visualize the binding of Aβ to the membrane as well as the BLM technique to monitor 
the membrane damage induced by Aβ upon binding.  
Materials and Methods 
Lipids. 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1-palmitoyl-2-oleoyl-sn-
glycero-3-phosphocholine (POPC), sphingomyelin (SM), cholesterol (Chol), and 
ganglioside monosialotetrahexosylganglioside (GM1) were purchased from Avanti Polar 
Lipids (Alabaster, AL) in powder form. Complex mixtures of these five constituents were 
made for analysis, and are outlined in Table 2. All other chemicals used were of reagent 
grade.  
Supported lipid monolayers. 
Preparation via Langmuir-Blodgett monolayer technique. Phospholipid monolayers were 
deposited on freshly cleaved mica (Ashville-Schoonmaker Mica Co., Newport News, 
VA) by the method of Langmuir-Blodgett (LB) deposition using a KSV-Nima LB 
microtrough (Biolin Scientific, Stockholm, Sweden). For sample preparation, solutions of 
lipid dissolved in chloroform at a concentration of 1 mg/mL (lipid/chloroform) were 
spread at the surface of the subphase and deposited on the mica substrates at a pressure of 
35 mN/m with a dipper arm speed of 2 mm/min. The mica slide was allowed to air-dry 
for 10 minutes before being placed in a dessicator for a 24-hour period, prior to further 
analysis. 
AFM / KPFM Imaging. AFM and KPFM imaging of monolayers supported on mica was 
performed using SmartSPM 1000 (AIST-NT) in air at room temperature and normal 
humidity using a MicroMasch gold coated cantilever (HQ:NSC14/Cr-Au) with a  
resonance frequency of 160 kHz and a spring constant of 5.0 N/m. KPFM imaging was 
performed in amplitude modulation mode (AM-KPFM) to achieve higher resolution and 
high sensitivity required for our biological samples than typical KPFM is capable of 
achieving. In this mode AM-KPFM imaging was done simultaneously with AFM 
imaging, AFM and AM-KPFM images of the sample correspond to the sample location38.  
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Data Processing and Analysis. Data collected was processed using SPIP and AIST-NT 
image processing software. The AFM topography images were plane corrected by means 
of global leveling and global bow removal and filtered using noise reduction caused 
while scanning with high resolution Z-scale (picometers).  KPFM images were not 
processed with any filters, to ensure the proper potential measurements; the raw data was 
used for average differences in electrical surface potential. Data was collected on 2 μm by 
2 μm and 5 μm by 5 μm high-resolution images of monolayer samples. At least 10 
images were analyzed for each sample. At least 3 samples were prepared for each 
membrane type. All quantitative results are presented as mean ± standard error of the 
mean (SEM), with significance determined using ANOVA tests. Any results determined 
to be significant are reported with a 95% confidence level. 
Aβ binding to the membrane.   
 
Preparation of Lipid Bilayers. Hydrated phospholipid bilayers were deposited on freshly 
cleaved mica (Ashville-Schoonmaker Mica Co., Newport News, VA) via vesicle fusion, 
as described in previous publications12, 39. Bilayers were covered with nanopure water 
and imaged in liquid using AFM.  
 
Aβ incubation on lipid membrane. Aβ1-42 (rPeptide, Bogart GA) was pretreated to ensure 
monomeric form according to Fezoui procedure40. Additional Aβ1-42 was made in the lab 
of Dr. Paul Fraser (University of Toronto, Toronto ON) and was also studied to confirm 
and compare the findings obtained for the Aβ form rPeptide. Aβ was suspended in 
HEPES buffer (20 mM HEPES, 100 mM NaCl, pH 7.4) at a concentration of 40 mM 
(Aβ/buffer). 100 μL of the Aβ solution was added to pre-formed membranes and 
incubated for increasing time periods; at the end of the time period for each membrane, 
excess Aβ was gently rinsed away in order to stop the fibrilization process, with complete 
hydration maintained at all times. The membrane with Aβ deposits was kept in Nanopure 
water. At least two repeats of the incubations were completed for amyloid from each 
source, totaling to 4 trials for each time point.   
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AFM imaging of lipid membrane in liquid. AFM imaging of hydrated membrane and Aβ 
incubated membrane samples on a mica substrate was performed using Magnetic-
Alternating-Current (MAC) mode on an Agilent AFM/SPM 5500 using Keysight Type II 
MAC mode rectangular cantilevers (force constant of 2.8 N/m and a resonance frequency 
in water of 30 kHz).  Membrane imaging was conducted at ambient room temperature in 
liquid cell in Nanopure water, with hydration of the membrane maintained at all times 
throughout imaging.  
 
Data processing and analysis. Data collected was processed using SPIP data processing 
software. The topography images were corrected via global levelling and global bow 
removal. Data was collected on 2 μm by 2 μm and 5 μm by 5 μm high-resolution images 
of membrane samples. All quantitative results are presented as mean ± SEM, with 
significant difference determined using ANOVA tests. Any differences determined to be 
significant are reported with a 95% confidence level. At least 3 samples were analyzed, 
each utilized a fresh batch of Aβ and lipid membranes, with at least 10 images taken for 
each sample from multiple locations on the membrane.  
Black Lipid Membrane (BLM) Studies.  
Preparation of BLM samples. Planar lipid bilayers were formed from a 15 mg/mL lipid 
solution in n-decane (Aldrich). The suspended bilayer was formed across the 200 µm 
aperture of a Delrin cup (Warner Instruments, Hamden, CT) by direct application of 
lipids41, Both cis (voltage command side) and trans (virtual ground) compartments of the 
cup cuvette contained 150 mM NaCl, 2 mM CaCl2, 10 mM Tris-HCl pH 7.4. 5 µM Aβ 
was added to the cis compartment of the cuvette. All measurements were performed at 
room temperature.  
Data recording and analysis. Currents across lipid bilayers were recorded with a Planar 
Lipid Bilayer Workstation (Warner Instruments, Hamden, CT). The cis compartment was 
connected to the head stage input and the trans compartment was held at virtual ground 
via a pair of matched Ag/AgCl electrodes. Signals from voltage-clamped BLM were 
high-pass-filtered at 2.1 kHz using an eight-pole Bessel filter LPF-8 (Warner 
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Instruments), digitized (Data Translation digitizer) and recorded	 on	 PC	 using	 in‐house	
analog‐to‐digital	converter	acquisition	software	developed	by	Elena	Pavlova. For the 
statistical analysis data were averaged from at least three independent experiments and 
analyzed using Origin software. Experiments were performed in three separate trials for 
each sample. Each recorded trace was analyzed to get obtain the mean value of 
conductance. Results are expressed as mean ± SEM.  
 
Results  
Lipid Composition of Model Systems Mimicking Healthy and AD Membrane States. 
Though there have been numerous studies on the interaction of lipid monolayers and 
membranes with Aβ6, 8, 12, 13, 25-30, 42, many studies are carried out using simple models, 
consisting of one to three lipid types, which do not provide a good model for neuronal 
membrane. Based on previous studies on the composition of the outer leaflet of the 
neuronal membrane6, 19, 33, 37, we designed three different multicomponent lipid models 
consisting of DPPC, POPC, sphingomyelin (SM), cholesterol (Chol), and ganglioside 
monosialotetrahexosylganglioside (GM1), which mimic healthy and AD neuronal 
membranes. The structure and properties of these lipids are shown in Table 1.  
Table 1: Structures and Properties of Lipids Studied. This table outlines information about the 
five constituents of the models studied: DPPC, POPC, SM, Chol, and GM1. Phospholipid phase 
at ambient room temperature is indicated as samples were studied under these conditions. Dipole 
moment value is included due to its relevance in the KPFM study portion of this work. Lipid 
structures were adapted from Avanti Polar Lipids.  
	
Structure and Name  Abbreviation  Phase at 
25⁰C 
Phase 
Transition 
Temperature 
(⁰C) 
Dipole 
Moment 
(D) 
 
DPPC  Gel  41  +0.8243 
 
POPC  Fluid  ‐2  +0.47344 
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SM  Gel  ~ 37  +0.3045 
 
Chol  ‐  ‐  +0.4046 
GM1  Fluid  ~ 20  ‐0.17143 
	
Three models consist of varying lipid ratios of the same composition: DPPC-POPC-SM-
Chol-GM1, shown in Table 2, and mimic healthy model membrane (HM), diseased 
model 1 accounting for decrease in GM1 content (D1) and diseased model 2 accounting 
for the decrease in both GM1 and SM content (D2). Such changes in membrane 
composition as a result of AD were observed in vivo19, 33.  
Table 2: Complex lipid models mimicking healthy and AD neuronal membranes. Lipid 
mixtures are all comprised of the same components but differ in their ratios (by weight) based on 
documented changes in membrane composition as a result of AD. 
Lipids  Ratio (by weight, %)  Ratio (by molarity, %)  Model Name 
DPPC – POPC – 
SM – Chol – GM1 
37 : 37 : 10 : 10 : 6  35.3 : 34.1 : 9.8 : 18.1 : 2.7  Healthy 
Model 
‐mimics a “healthy” neuron 
DPPC – POPC – 
SM – Chol – GM1 
39 : 39 : 10 : 10 : 2  36.5 : 35.2 : 9.7 : 17.8 : 0.09  Diseased 1 
(D1) Model 
‐mimics a neuron beginning to enter the “diseased” state with a decrease in the GM1 content 
(Diseased 1)  
DPPC – POPC – 
SM – Chol – GM1 
42 : 42 : 4 : 10 : 2  39.4 : 38.0 : 3.9 : 17.8 : 0.09  Diseased 2 
(D2) Model 
‐mimics an increasingly “diseased” neuron with a decrease in both GM1 and SM content 
(Diseased 2)  
 
The healthy model (Table 2) has five constituents commonly found in the outer leaflet of 
a general healthy neuronal cell membrane. Mass ratios were utilized to allow for easier 
comparison to our earlier studies12, 39 and relative ratios were decided upon based on 
extrapolation from studies of lipid content in neuronal cells47. The D1 model was chosen 
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to correlate with the reductions in gangliosides observed in membranes in several regions 
of AD brains compared to that of control brains, as well as with decreases in GM1 
content as AD progresses19, 29. The D2 model has a decrease in both GM1 and SM 
compared to our model of a healthy neuronal membrane. This decreased amount of SM 
was chosen based on reported decrease in SM content due to increased sphingomyelinase 
activity in association with AD15.  
Study of Monolayer Morphology and Electrical Surface Potential. Using these 
combinations of lipids, we prepared supported monolayers of the three models and used 
AFM and KPFM in order to study the morphology and electrical surface potential 
distribution of each model monolayer. AFM allows for topographical imaging of a 
sample with nanoscale resolution, making it ideal for investigating the changes in 
monolayer morphology. KPFM is a variation of an AFM and has been shown useful for 
mapping electrical surface potential of a lipid monolayer at the nanoscale38.  
Figure 1 depicts the changes in topography (AFM), and electrical surface potential 
(KPFM), observed between the three models. 
The healthy model (Figure 1A) shows the network of interconnected nanodomains spread 
across the monolayer. The topographical nanodomains have the average differences in 
height (Δh) of 0.986 ± 0.024 nm between higher and lower domains. The lateral 
dimensions of the higher domains ranged from 22.5 x 40.1nm up to over 200 x 52 nm. 
The lower domains were mostly small, less than 20 nm across, with few larger areas up to 
150nm across. KPFM images of the monolayer corresponding to this model show some 
minor fluctuations in electrical surface potential (V) (Figure 1D), though no discernible 
patterns in ΔV are observed. The average roughness (variation in ΔV between higher and 
lower domains) of the sample is 24.64 ± 1.10 mV (as seen in Table 3).  
 
	 10
  
 
Figure 1: Comparison of monolayer topography and electrical surface potential for three 
models.  AFM topography (in gold) and KPFM electrical surface potential (in blue) images are 
shown for healthy (A/D), diseased: D1 (B/E), and D2 (C/F) model systems in monolayer form. 
Cross sections of topography features are below each topography image. Scale bar denotes 500 
nm.   
	
In the AFM topography of the D1 model (Figure 1B), irregularly shaped interconnected 
higher and lower domains are observed. The higher domains are larger in area than in the 
healthy model, spanning up to 525 nm. The lower domains range from 35 to 200 nm 
across. The higher domains appear only slightly higher than those in the healthy model, 
with average Δh values of 1.051 ± 0.016 nm as compared to the healthy model (0.986 
nm). The KPFM image of the D1 model (Figure 1E) shows organized, nanoscale 
electrostatic domains with the differences in electrical surface potential ΔV of 70.47 ± 
5.41 mV, the highest average ΔV observed across the three samples. Topographic (AFM) 
and electrostatic (KPFM) nanodomains correlate with each other for the D1 model. 
Lower domains that are more disordered in nature are present in both the D1 and healthy 
model. However in the D1 model, these lower domains are larger in area than the healthy 
model; in the D1 model lower domains reached sizes of 200 nm across, whereas domains 
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in the healthy model spanned up to 20 nm across. According to Connelly et al., Aβ is able 
to directly interact with a DOPC lipid bilayer and insert itself to form ion-conductive 
pores with an average outer diameter of 7.8 - 8.3 nm48. We expect that Aβ would most 
easily form pores in less ordered areas of the membrane corresponding with the regions 
in our monolayer models.  
The D2 model (Figure 1C) shows a disruption of the larger, more ordered domains 
observed in the D1 model; it contains irregularly shaped features but smaller in area and 
more plentiful in number. They are quite narrow, with an average width of about 25 nm, 
and do not exceed 180 nm in length. The size of the lower domains are decreased when 
compared to the D1 model, with widths ranging from 27 to 40 nm compared with the 
widths of up to 200 nm seen in the D1 model. We also observe a drastic decrease in the 
average difference in height between higher and lower domains for the D2 model when 
compared to the other samples studied. The nanodomains observed in the D2 model had 
an average Δh of 0.500 ± 0.03 nm, which is significantly smaller than both the healthy 
and D1 models. This is likely due to the reduced SM content of this model, causing 
reduced lipid tail ordering. As seen from KPFM images (Fig 1F), the D2 model 
electrostatic domains present in the KPFM images did not correlate to AFM topography 
domains for this model (Figure 1C). An average ΔV of 11.63 ± 0.59 was measured for 
this model the smallest average ΔV observed between all the models. Results of the 
monolayer study are summarized in Table 3, which compares the average Δh and ΔV 
values for each of the three models studied.  
Table 3: Summary of Statistical Analysis of Mixed Lipid Monolayer Samples. Average 
numbers for Δh (difference in height) and ΔV (difference in electrical surface potential), 
determined from AFM and KPFM images of monolayers corresponding to healthy, D1 and D2 
models.  
  Healthy Model  Diseased 1 Model  Diseased 2 Model 
Topographical Domains 
Δh  0.986 ± 0.02 nm  1.051 ± 0.016 nm  0.500 ± 0.03 nm 
Features in Electrical Surface Potential 
ΔV  24.64 ± 1.10 mV  70.47 ± 5.41 mV  11.63 ± 0.59 mV 
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These results demonstrate that differences in topographical nanoheterogeneity and 
electrical surface potential are clearly seen in all three models (healthy, D1 and D2), 
which influence the interaction of each membrane with the charged Aβ peptide, discussed 
in the next section.  
Model Membranes and their Interactions with Aβ.  
BLM Study: Amyloid Effect on Membrane Permeability. We used Black Lipid 
Membrane (BLM) techniques to study the effects of Aβ on lipid bilayer conductance. 
This method allows for the measurement of ion currents across the membrane and 
membrane permeability to ions49. We compared currents measured across lipid bilayers 
of three different compositions corresponding to our model membranes shown in Table 2. 
These membranes were studied both in the absence and the presence of Aβ (1-42) peptide 
in order to investigate changes in membrane permeability caused by Aβ binding.  
The conductance was observed in the control/“healthy” model without the addition of the 
Aβ (Figure 2A). The addition of 5 µM Aβ to the compartment of the cuvette containing 
the model led to an increase in noise amplitude with the following increase in 
conductance level. Although we recorded the increase in current, this increase was not 
statistically significant for the healthy model (Figure 2A Left panel, p=0.053, n=4). For 
the D1 membrane model, we found that the addition of Aβ caused a significant increase 
in the conductance of the membrane, which further increased with time. This effect is 
apparent from  Figure 2B (p=5x10-6, n=11), which illustrates an increase in conductance 
after 15 minutes of Aβ incubation compared to the conductance after 5 minutes of Aβ 
incubation. Finally, for the D2 model, we also observed that the addition of Aβ led to a 
significant increase (p=0.003, n=8) in the conductance of the membrane, which 
developed over the period of time. However, this increase was less than the increase in 
the conductance observed in the D1 model (Figure 2C). Overall, we established that the 
current across all of the tested membranes progressively increased with time reflecting 
membrane disintegration upon interaction with Aβ. Results of the quantitative 
comparison of the Aβ-induced conductance of tested model membranes are summarized 
in Figure 3.  
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Figure 2: Ion currents observed across the membrane: healthy model (A), D1 model (B), 
and D2 model (C). Lipid membranes were suspended between symmetric aqueous solutions of 
150 mM NaCl, 2 mM CaCl2, 10 mM Tris pH 7.4. The left panel for each section shows average 
current at the voltage amplitude of 50 mV under control conditions (no additions), in 5 min after 
induction of conductance by the Aβ, in 15 min after induction of conductance by the Aβ. 
Representative currents at 50 mV are shown in the right panel. * indicates significantly lower 
current. 
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Figure 3: Comparison of the currents induced by 5 µM of Aβ on different model 
membranes at voltage amplitude of 50 mV. * indicates significantly lower current. 
	
Of the three models, we found that in the presence of Aβ the D1 and D2 models both had 
higher conductance measurements than the healthy model. The highest current amplitude 
was observed in the D1 model membranes (in Fig 3, for 5 min (left): p=0.03, n=11; for 
15 min (right): p=0.3, n=3).  
Finally, we studied the interactions of Aβ with the membrane models using AFM, in 
order to determine how the nanoscale heterogeneity in topography and electrical surface 
potential observed in the monolayer study affects peptide-membrane interaction. Figure 4 
illustrates schematically the presence of lipid domains (differing in height and electrical 
surface potential) in the complex multi-lipid membrane. 
AFM Study: Amyloid Incubation on Model Membrane Systems. We formed 
supported membranes (bilayers) for each of the three lipid models and incubated 
solutions of Aβ in HEPES buffer in its monomeric form atop the membrane for 1, 4, 6, 
and 24 hours in buffer and imaged them with AFM in nanopure water, in order to 
maintain membrane hydration. We looked at four main factors: how Aβ binds to the 
membrane; the amount of Aβ binding and accumulating over time; the morphology of the 
Aβ aggregates on the membrane; and the presence of Aβ -induced membrane damage.  
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The differences in Aβ binding to the membrane and accumulation over time are shown in 
Figure 5 and results are summarized in Table 4.  
	
Figure 4: Schematic of Aβ interacting with a model membrane (not to scale). Arrangement of 
lipids present model bilayer system and phase separation leads to membrane nonhomogeneity, i.e., 
the presence of nanodomains, both topographical (Δh) and electrostatic (ΔV).   
	
We followed the changes in the surface roughness with time which reflects Aβ binding to 
the membrane and accumulation of amyloid deposits on the membrane. In the healthy 
model, we observed the surface roughness increasing over time as the larger clusters are 
formed. This suggests that Aβ accumulation progressively increases with increasing 
incubation time. After 1 hour of incubation (Figure 5A) we see a uniform layer of 
aggregates randomly spread across the surface of the membrane, with a roughness of 
0.267 ± 0.05 nm. The accumulation of Aβ aggregates on the membrane increase with 
time, with roughness increasing as incubation time increases: after 4 hours of incubation, 
average surface roughness was 0.536 ± 0.11 nm; after 6 hours of incubation (Figure 5D), 
roughness was 0.541 ± 0.074 nm; and after 24 hours of incubation, Aβ accumulation 
gave a surface roughness of 1.596 ± 0.19 nm. This is a progressive increase in the size of 
the Aβ clusters on the membrane.  
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Figure 5: Comparison of Aβ Incubation on Three Different Model Membranes for 1 and 6 
hours. AFM images in liquid illustrate the difference in Aβ accumulation between 1 and 6 hours 
of incubation time on a healthy model membrane (A and D respectively), a diseased 1 membrane 
(B and E) and a diseased 2 membrane (C and F). Image sizes are shown via the ruler scale bar in 
the left bottom hand corner of each image (the scale bar for A, D, E, and F corresponds to 1 µm; 
the scale bar for B and C corresponds to 500 nm).  
	
Table 4: Changes of Surface Roughness with Time due to Aβ Accumulation on the 
Membrane. Aβ accumulation is quantified via surface roughness analysis for the HM, D1 and 
D2 models during 1h, 4h, 6h, and 24 h of incubation. 
  Surface Roughness
Healthy Model
(nm) 
Diseased 1 Model
(nm) 
Diseased 2 Model
(nm) 
1 Hour  0.267 ± 0.05 0.487 ± 0.027 0.38 ± 0.033
4 Hour  0.536 ± 0.11 0.42 ± 0.03 1.366 ± 0.12
6 Hour  0.541 ± 0.074 0.57 ± 0.11 0.366 ± 0.045
24 Hour  1.59 ± 0.19 0.44 ± 0.19 0.546 ± 0.026
	
 
In the D1 model, we saw a change in the accumulation pattern over time, in comparison 
to the healthy model. After 1 hour of incubation (Figure 5B), we observed a higher 
surface roughness in the D1 model, 0.487 ± 0.027 nm, than in the healthy model. This 
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indicates more Aβ accumulation than in the healthy model. Although there is no 
discernible difference in the size and shape of Aβ species on the surface, in both models 
we saw small, spherical and irregularly shaped oligomers and aggregates. However, as 
time progressed, the roughness fluctuated: after 4 hours of incubation, we saw a decrease 
in surface roughness to 0.42 ± 0.03 nm; after 6 hours (Figure 5E), the surface roughness 
increased slightly to 0.57 ± 0.11 nm; and after 24 hours of incubation time, the average 
roughness decreased again to its lowest of all the time periods, to 0.44 ± 0.19 nm.  
Finally, in the D2 model, we saw an initial large accumulation of Aβ species, indicated 
by an initial large increase in roughness, followed by a dramatic decrease. After 1 hour of 
incubation (Figure 5C), the surface roughness was 0.38 ± 0.03 nm, which almost 
quadrupled to 1.36 ± 0.12 nm after 4 hours. This indicates an initial large accumulation of 
Aβ on the surface of the membrane, without much membrane damage. However, after 6 
hours (Figure 5F), we saw a large decrease in roughness of the model, with an average 
roughness of 0.366 ± 0.045 nm. At this point, Aβ clusters likely penetrated into the 
membrane, leading to a dramatic decrease in surface roughness, similar to what has been 
observed in fluid membranes12, 50. After 24 hours, the roughness increased slightly, to 
0.546 ± 0.026 nm, suggesting a continuation of accumulation atop the Aβ-disrupted 
membrane.  
Discussion 
In this investigation, summarized in Table 5, we designed and studied three complex lipid 
models mimicking a healthy neuronal membrane, and two diseased states of the 
membrane (D1 and D2), mimicking changes in lipid compositions occurring in AD 
neurons. AFM and KPFM studies of monolayers show that the D1 and D2 models have 
different nanoscale surface morphologies (topographical domains and electrostatic 
domains) from each other and as well as compared with the healthy model.  
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Table 5: Summary of Results. AFM/KPFM study on topographical and electrical surface 
potential features of the models in monolayer form; Black Lipid Membrane analysis on the 
permeability of each model and the effect of Aβ on this conductance; and AFM liquid imaging of 
Aβ accumulation over time on each model membrane. 
  Healthy Model Diseased 1 Model  Diseased 2 Model 
Monolayer Morphology – AFM / KPFM Analysis 
Topographical  
Δh 
0.986 ± 0.02 nm  1.051 ± 0.016 nm  0.500 ± 0.03 nm 
Lower than Healthy 
Model 
Electrostatic 
Surface Potential  
ΔV 
24.64 ± 1.10 mV  70.47 ± 5.41 mV 
Higher than Healthy 
Model 
11.63 ± 0.59 mV 
Lower than Healthy 
Model 
Black Lipid Membrane (BLM) Analysis 
Pore Forming 
Activity (PFA) 
No significant 
increase in PFA 
with addition of 
amyloid 
Highest PFA of three 
systems studied 
Significant increase in PFA 
with addition of amyloid 
Significant increase in 
PFA with addition of 
amyloid 
Aβ Binding to Model Membranes 
Aβ Accumulation 
Over Time 
measured via 
Roughness 
Measurements 
Increases with 
time 
Fluctuate between 
increases and decreases 
over time 
Indicative of amyloid 
penetrating into 
membrane 
Initial increase followed 
by large decrease 
Indicative of an initial 
accumulation event 
preceding membrane 
disruption/penetration 
	
 
Lipid domains originate from lipid separation commonly observed in multi-component 
lipid systems. Different lipids exist in different phases at ambient room temperature, such 
as liquid crystalline (Lc), liquid disordered (Ld), or with the presence of Chol, cholesterol-
induced liquid-ordered phase domains, (Lo). These higher domains are likely to be rich in 
DPPC, SM, and Chol molecules, (Table 1), as well as GM1 molecules, known to 
associate with saturated phospholipids, SM, and Chol in lipid rafts. The lower domains 
are likely areas of high POPC concentration, as POPC is found in Ld phase at room 
temperature. The changes in lipid composition in HM, D1 and D2 models, including 
GM1 and cholesterol, result in changes in membrane morphology, i.e. domain 
organization, size and ordering. These domains also differ in electrical surface potential. 
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We previously showed that similar nanoscale topographical and electrostatic domains are 
formed in a simple DOPC-Chol model and their presence causes preferential amyloid 
binding39. We showed that such changes in domain morphology and electrical surface 
potential in HM, D1 and D2 models influence their interaction with Aβ, and amyloid-
induced damage. 
Our BLM study shows that Aβ binds to the membrane and induces an increase in 
membrane conductance (ion permeability), which is a result of pore formation induced by 
amyloid.  The significantly higher pore forming activity of the two diseased membrane 
models compared to the healthy model (Figure 2 and Table 5) supports the idea that the 
differences in membrane composition can have a strong effect on the interaction of the 
Aβ with the membrane and the extent to which the Aβ can cause damage and alteration 
of normal cell function by changing membrane permeability. This is consistent with 
different domain distribution and morphologies observed in each model with the 
monolayer studies. 
Our AFM images illustrate Aβ binding to the membrane and indicate less penetration of 
Aβ into the healthy model membrane in good correlation with BLM results.  
According to the proposed mechanisms of Aβ interaction with the membrane 50, 
depending on the membrane state, Aβ may either adsorb onto the surface of the lipid 
membrane (as seen in the healthy model) or partially penetrate into the membrane, 
causing membrane disruption and pore formation48, 50. The multiple types of membrane 
interaction that Aβ is capable of can be attributed to its complex charge distribution; this 
distribution allows for Aβ to bind to surfaces of varying charges and hydrophobicity51.  
Both the D1 and D2 models show higher penetration of Aβ into the membrane, inducing 
membrane damage, which correlates with the much higher membrane permeability 
recorded by BLM in D1 and D2 models. The differences in Aβ accumulation as well as 
differences in membrane disruption further show the significant effect of membrane lipid 
composition as well as nanoheterogeneity on its interaction with Aβ.  
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The importance of the effect of the composition of the membrane itself on amyloid - 
membrane interactions is of even greater interest as it has been shown recently that Aβ 
peptides share many similarities with antimicrobial peptides (AMP), which specifically 
recognize and kill bacterial cells through selective membrane-mediated recognition 
mechanism, causing disintegration of the bacterial membrane without affecting the host 
cell52. AMP and Aβ share common characteristics, including the ability to form fibrils in 
solution, capabilities of membrane interaction, ability to form ion channels and defects in 
the membrane52. In vitro studies have shown that Aβ has antimicrobial activity against 
eight common and clinically relevant microorganisms with a potency equivalent to or 
greater than AMP, which suggests the potential of Aβ is an unrecognized AMP of the 
innate immune system53. In fact, an exciting recent study showed the ability of Aβ to 
mediate the entrapment of unattached microbes in the brain, further suggesting that Aβ 
has protective roles in innate immunity 54acting as an AMP in the brain.  
AMPs are known to be very specific in recognizing the structure of bacterial membranes 
through electrostatic interactions. Similar to AMPs, Aβ is negatively charged (-3)51 and 
thus may share this electrostatic mechanism. This allows Aβ to recognize changes in 
membrane structure and integrity through electrostatic interactions and the presence of 
electrostatic nanodomains in neuronal model membranes. This alteration in membrane 
composition and structure being a factor in the onset of AD also may help to explain why 
some people maintain normal cognitive abilities despite the presence of Aβ plaques55.  
 Conclusions 
In summary, we designed model lipid membranes which mimic the neuronal cell 
membrane in healthy and diseased states. We demonstrated that healthy and diseased 
model membranes differ in their nanoscale structure, which significantly influence the 
interaction of these membranes with Aβ (1-42). The diseased membrane models are more 
susceptible to interaction with Aβ and its damaging effects than a healthy membrane 
model. Based on our data and Aβ – AMP similarities reported in literature we propose a 
new hypothesis for the mechanism of amyloid toxicity in which the neuronal membrane 
changes play a crucial role: i.e. when neuronal cellular membrane changes in composition 
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and properties due to aging or AD it becomes recognized by Aβ as foreign or “bacteria-
like” membrane through electrostatic interactions and therefore undergo amyloid attack 
and disintegration.  Therefore, sustaining neuronal cellular membrane in a healthy state 
may reduce the damaging effects of Aβ and serve as a preventative strategy against 
Alzheimer`s disease.  
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